Literature DB >> 33536459

Combined analysis of miR-200 family and its significance for breast cancer.

Andrea Fontana1, Raffaela Barbano2, Elisa Dama3, Barbara Pasculli2, Michelina Rendina2, Maria Grazia Morritti4, Valentina Melocchi3, Marina Castelvetere5, Vanna Maria Valori4, Sara Ravaioli6, Sara Bravaccini6, Luigi Ciuffreda7, Paolo Graziano5, Evaristo Maiello4, Massimiliano Copetti1, Vito Michele Fazio2, Manel Esteller8,9,10,11, Fabrizio Bianchi3, Paola Parrella12.   

Abstract

While the molecular functions of miR-200 family have been deeply investigated, a role for these miRNAs as breast cancer biomarkers remains largely unexplored. In the attempt to clarify this, we profiled the miR-200 family members expression in a large cohort of breast cancer cases with a long follow-up (H-CSS cohort) and in TCGA-BRCA cohort. Overall, miR-200 family was found upregulated in breast tumors with respect to normal breast tissues while downregulated in more aggressive breast cancer molecular subtypes (i.e. Luminal B, HER2 and triple negative), consistently with their function as repressors of the epithelial-to-mesenchymal transition (EMT). In particular miR-141-3p was found differentially expressed in breast cancer molecular subtypes in both H-CSS and TCGA-BRCA cohorts, and the combined analysis of all miR-200 family members demonstrated a slight predictive accuracy on H-CSS cancer specific survival at 12 years (survival c-statistic: 0.646; 95%CI 0.538-0.754).

Entities:  

Year:  2021        PMID: 33536459     DOI: 10.1038/s41598-021-82286-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  23 in total

1.  miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer.

Authors:  S Uhlmann; J D Zhang; A Schwäger; H Mannsperger; Y Riazalhosseini; S Burmester; A Ward; U Korf; S Wiemann; O Sahin
Journal:  Oncogene       Date:  2010-05-31       Impact factor: 9.867

2.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

Review 3.  The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis.

Authors:  Manav Korpal; Yibin Kang
Journal:  RNA Biol       Date:  2008 Jul-Sep       Impact factor: 4.652

4.  miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family.

Authors:  Feng Ye; Hailin Tang; Qing Liu; Xinhua Xie; Minqing Wu; Xiaoping Liu; Bo Chen; Xiaoming Xie
Journal:  J Transl Med       Date:  2014-01-21       Impact factor: 5.531

5.  miR-200c inhibits breast cancer proliferation by targeting KRAS.

Authors:  Cailu Song; Long-Zhong Liu; Xiao-Qing Pei; Xiaoping Liu; Lu Yang; Feng Ye; Xinhua Xie; Jianping Chen; Hailin Tang; Xiaoming Xie
Journal:  Oncotarget       Date:  2015-10-27

6.  MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells.

Authors:  Lourdes Sánchez-Cid; Mònica Pons; Juan José Lozano; Nuria Rubio; Marta Guerra-Rebollo; Aroa Soriano; Laia Paris-Coderch; Miquel F Segura; Raquel Fueyo; Judit Arguimbau; Erika Zodda; Raquel Bermudo; Immaculada Alonso; Xavier Caparrós; Marta Cascante; Arash Rafii; Yibin Kang; Marian Martínez-Balbás; Stephen J Weiss; Jerónimo Blanco; Montserrat Muñoz; Pedro L Fernández; Timothy M Thomson
Journal:  Oncotarget       Date:  2017-09-07

7.  miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/β-Catenin Axis.

Authors:  Bingjie Liu; Ruikai Du; Lei Zhou; Jiahui Xu; Song Chen; Ji Chen; Xiaoli Yang; Dong-Xu Liu; Zhi-Ming Shao; Lixing Zhang; Zuoren Yu; Ni Xie; Jun-Lin Guan; Suling Liu
Journal:  Theranostics       Date:  2018-11-10       Impact factor: 11.556

8.  Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer.

Authors:  Maria Amorim; João Lobo; Mário Fontes-Sousa; Helena Estevão-Pereira; Sofia Salta; Paula Lopes; Nuno Coimbra; Luís Antunes; Susana Palma de Sousa; Rui Henrique; Carmen Jerónimo
Journal:  Front Genet       Date:  2019-09-11       Impact factor: 4.599

9.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

10.  Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel.

Authors:  Barbara Pasculli; Raffaela Barbano; Michelina Rendina; Andrea Fontana; Massimiliano Copetti; Tommaso Mazza; Vanna Maria Valori; Maria Morritti; Evaristo Maiello; Paolo Graziano; Roberto Murgo; Vito Michele Fazio; Manel Esteller; Paola Parrella
Journal:  Sci Rep       Date:  2019-10-17       Impact factor: 4.379

View more
  6 in total

1.  Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer.

Authors:  Esther Navarro-Manzano; Ginés Luengo-Gil; Rocío González-Conejero; Elisa García-Garre; Elena García-Martínez; Esmeralda García-Torralba; Asunción Chaves-Benito; Vicente Vicente; Francisco Ayala de la Peña
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

2.  Menopausal Transition: Prospective Study of Estrogen Status, Circulating MicroRNAs, and Biomarkers of Bone Metabolism.

Authors:  Jiri Baloun; Aneta Pekacova; Laszlo Wenchich; Hana Hruskova; Ladislav Senolt; Xiao Svec; Karel Pavelka; Jan J Stepan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-13       Impact factor: 6.055

3.  Exploring the Potential of Exosome-Related LncRNA Pairs as Predictors for Immune Microenvironment, Survival Outcome, and Microbiotain Landscape in Esophageal Squamous Cell Carcinoma.

Authors:  Fangchao Zhao; Zhirong Li; Zefang Dong; Zengying Wang; Pengfei Guo; Dengfeng Zhang; Shujun Li
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 4.  MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Authors:  Cyril Sobolewski; Laurent Dubuquoy; Noémie Legrand
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

5.  Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.

Authors:  Chiara Fischer; Thomas M Deutsch; Andrey Turchinovich; Markus Wallwiener; Manuel Feisst; Nathalie Rippinger; Fabian Riedel; Andreas D Hartkopf; Sara Y Brucker; Christoph Domschke; Carlo Fremd; Laura Michel; Barbara Burwinkel; Andreas Schneeweiss
Journal:  Arch Gynecol Obstet       Date:  2022-03-02       Impact factor: 2.493

6.  SYNCRIP Modulates the Epithelial-Mesenchymal Transition in Hepatocytes and HCC Cells.

Authors:  Veronica Riccioni; Flavia Trionfetti; Claudia Montaldo; Sabrina Garbo; Francesco Marocco; Cecilia Battistelli; Alessandra Marchetti; Raffaele Strippoli; Laura Amicone; Carla Cicchini; Marco Tripodi
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.